{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:33:37Z","timestamp":1788885217841,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.humpath.2025.105823","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T19:38:00Z","timestamp":1748720280000},"page":"105823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immunostaining for polycomb group protein EZH2 as a diagnostic tool to differentiate urothelial carcinoma in situ from benign lesions"],"prefix":"10.1016","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5340-8768","authenticated-orcid":false,"given":"Toshihiko","family":"Iizuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayataka","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Motoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2025.105823_bib1","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.juro.2011.12.020","article-title":"Urothelial carcinoma in situ of the bladder","volume":"187","author":"Humphrey","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.humpath.2025.105823_bib2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000049765","article-title":"Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861","volume":"40","author":"Jakse","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.humpath.2025.105823_bib3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.urolonc.2010.01.001","article-title":"Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy","volume":"30","author":"Wheat","year":"2012","journal-title":"Urol Oncol"},{"key":"10.1016\/j.humpath.2025.105823_bib4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/PAI.0000000000000401","article-title":"Flat urothelial lesions with atypia: interobserver concordance and added value of immunohistochemical profiling","volume":"26","author":"Lawless","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.humpath.2025.105823_bib5","doi-asserted-by":"crossref","unstructured":"McKenney JK. Precursor lesions of the urinary bladder. Histopathology (Oxf) n.d.74:68\u201376. https:\/\/doi.org\/10.1111\/his.13762.","DOI":"10.1111\/his.13762"},{"key":"10.1016\/j.humpath.2025.105823_bib6","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/00000478-200108000-00013","article-title":"Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens","volume":"25","author":"McKenney","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2025.105823_bib7","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.humpath.2012.08.011","article-title":"Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases","volume":"44","author":"Oliva","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2025.105823_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13000-020-00984-2","article-title":"CK20 versus AMACR and p53 immunostains in evaluation of urothelial carcinoma in situ and reactive atypia","volume":"15","author":"Neal","year":"2020","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.humpath.2025.105823_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5858\/arpa.2016-0411-OA","article-title":"CK20 and p53 immunohistochemical staining patterns in urinary bladder specimens with equivocal atypia","volume":"142","author":"Arias-Stella","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2025.105823_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.molcel.2008.11.004","article-title":"Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms","volume":"32","author":"Margueron","year":"2008","journal-title":"Mol Cell"},{"key":"10.1016\/j.humpath.2025.105823_bib11","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1076997","article-title":"Role of histone H3 lysine 27 methylation in Polycomb-group silencing","volume":"298","author":"Cao","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.humpath.2025.105823_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bbrc.2019.07.039","article-title":"EZH2 regulates PD-L1 expression via HIF-1\u03b1 in non-small cell lung cancer cells","volume":"517","author":"Zhao","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.humpath.2025.105823_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/bjc.2011.551","article-title":"The role of EZH2 in tumour progression","volume":"106","author":"Chang","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2025.105823_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4143\/crt.2014.46.3.209","article-title":"Regulation and role of EZH2 in cancer","volume":"46","author":"Yamaguchi","year":"2014","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.humpath.2025.105823_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36164-y","article-title":"Increased expression of EZH2 indicates aggressive potential of urothelial carcinoma of the bladder in a Chinese population","volume":"8","author":"Zhou","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.humpath.2025.105823_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2022.100541","article-title":"The combined use of long non-coding RNA HOTAIR and polycomb group protein EZH2 as a prognostic marker of lung adenocarcinoma","volume":"31","author":"Iizuka","year":"2022","journal-title":"Cancer Treatment and Research Communications"},{"key":"10.1016\/j.humpath.2025.105823_bib17","article-title":"Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2025.105823_bib18","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.18632\/oncotarget.6612","article-title":"Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis","volume":"7","author":"Jiang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2025.105823_bib19","article-title":"Positive results for tazemetostat in follicular lymphoma","volume":"8","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.humpath.2025.105823_bib20","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/1078-0432.CCR-19-1351","article-title":"Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer","volume":"26","author":"Zhou","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2025.105823_bib21","doi-asserted-by":"crossref","unstructured":"Shinozaki-Ushiku A, Ushiku T, Morita S, Anraku M, Nakajima J, Fukayama M. Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma. Histopathology (Oxf) n.d.70:722\u2013733. https:\/\/doi.org\/10.1111\/his.13123.","DOI":"10.1111\/his.13123"},{"key":"10.1016\/j.humpath.2025.105823_bib22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1746-1596-7-86","article-title":"Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors","volume":"7","author":"Haj\u00f3si-Kalcakosz","year":"2012","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.humpath.2025.105823_bib23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13000-015-0392-z","article-title":"EZH2 is a sensitive marker of malignancy in salivary gland tumors","volume":"10","author":"Haj\u00f3si-Kalcakosz","year":"2015","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.humpath.2025.105823_bib24","article-title":"High expression of EZH2 as a marker for the differential diagnosis of malignant and benign myogenic tumors","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.humpath.2025.105823_bib25","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.urolonc.2010.09.005","article-title":"Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder","volume":"30","author":"Wang","year":"2012","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"key":"10.1016\/j.humpath.2025.105823_bib26","doi-asserted-by":"crossref","first-page":"258.e1","DOI":"10.1016\/j.urolonc.2016.02.011","article-title":"Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer","volume":"34","author":"Warrick","year":"2016","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"key":"10.1016\/j.humpath.2025.105823_bib27","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.5375","article-title":"p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies","volume":"250","author":"Singh","year":"2020","journal-title":"J Pathol"},{"key":"10.1016\/j.humpath.2025.105823_bib28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00428-018-2354-9","article-title":"Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications","volume":"472","author":"Barth","year":"2018","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2025.105823_bib29","doi-asserted-by":"crossref","first-page":"6556","DOI":"10.1158\/1078-0432.CCR-12-3946","article-title":"EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non\u2013small cell lung carcinoma","volume":"19","author":"Behrens","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2025.105823_bib30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/cancers10040100","article-title":"Bladder cancer: new insights into its molecular pathology","volume":"10","author":"Inamura","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.humpath.2025.105823_bib31","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1038\/s41467-023-41139-3","article-title":"Proteogenomics of different urothelial bladder cancer stages reveals distinct molecular features for papillary cancer and carcinoma in situ","volume":"14","author":"Yao","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.humpath.2025.105823_bib32","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/ijc.21852","article-title":"Understanding urothelial carcinoma through cancer pathways","volume":"119","author":"Schulz","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2025.105823_bib33","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1158\/1078-0432.CCR-18-3121","article-title":"Clinical and genomic implications of luminal and basal subtypes across carcinomas","volume":"25","author":"Zhao","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2025.105823_bib34","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.humpath.2025.105823_bib35","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2021\/e2587","article-title":"Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: association with clinicopathological features and outcomes","volume":"76","author":"Ravanini","year":"2021","journal-title":"Clinics (S\u00e3o Paulo)"},{"key":"10.1016\/j.humpath.2025.105823_bib36","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1038\/sj.onc.1207706","article-title":"Activated p53 suppresses the histone methyltransferase EZH2 gene","volume":"23","author":"Tang","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2025.105823_bib37","doi-asserted-by":"crossref","first-page":"27107","DOI":"10.3390\/ijms161126000","article-title":"EZH2 in bladder cancer, a promising therapeutic target","volume":"16","author":"Mart\u00ednez-Fern\u00e1ndez","year":"2015","journal-title":"IJMS"},{"key":"10.1016\/j.humpath.2025.105823_bib38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1476-4598-9-108","article-title":"MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1\u03b1\/HIF-1\u03b2","volume":"9","author":"Cao","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.humpath.2025.105823_bib39","doi-asserted-by":"crossref","first-page":"44660","DOI":"10.18632\/oncotarget.6350","article-title":"Mutant p53 induces EZH2 expression and promotes epithelial\u2013mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing","volume":"6","author":"Jiang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2025.105823_bib40","first-page":"86","article-title":"Urothelial carcinoma in situ: diagnostic update","volume":"53","author":"McKenney","year":"2021","journal-title":"Pathology (Phila, Pa)"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725001108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725001108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T17:19:25Z","timestamp":1759771165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817725001108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":40,"alternative-id":["S0046817725001108"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2025.105823","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunostaining for polycomb group protein EZH2 as a diagnostic tool to differentiate urothelial carcinoma in situ from benign lesions","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2025.105823","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105823"}}